Literature DB >> 25815292

Clinical perspective on PROSE: does VeriStrat testing improve selection of second-line treatment for patients with non-small cell lung cancer?

Jimmy Ruiz1, W Jeffrey Petty1.   

Abstract

Entities:  

Year:  2015        PMID： 25815292      PMCID： PMC4356851          DOI： 10.3978/j.issn.2305-5839.2015.01.22

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  15 in total

1.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

Authors:  Nick Thatcher; Alex Chang; Purvish Parikh; José Rodrigues Pereira; Tudor Ciuleanu; Joachim von Pawel; Sumitra Thongprasert; Eng Huat Tan; Kristine Pemberton; Venice Archer; Kevin Carroll
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

2.  Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.

Authors:  David P Carbone; Keyue Ding; Heinrich Roder; Julia Grigorieva; Joanna Roder; Ming-Sound Tsao; Lesley Seymour; Frances A Shepherd
Journal:  J Thorac Oncol       Date:  2012-11       Impact factor: 15.609

3.  Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Authors:  Marina Chiara Garassino; Olga Martelli; Massimo Broggini; Gabriella Farina; Silvio Veronese; Eliana Rulli; Filippo Bianchi; Anna Bettini; Flavia Longo; Luca Moscetti; Maurizio Tomirotti; Mirko Marabese; Monica Ganzinelli; Calogero Lauricella; Roberto Labianca; Irene Floriani; Giuseppe Giaccone; Valter Torri; Alberto Scanni; Silvia Marsoni
Journal:  Lancet Oncol       Date:  2013-07-22       Impact factor: 41.316

4.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

Authors:  Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

5.  A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.

Authors:  Thomas E Stinchcombe; Joanna Roder; Amy H Peterman; Julia Grigorieva; Carrie B Lee; Dominic T Moore; Mark A Socinski
Journal:  J Thorac Oncol       Date:  2013-04       Impact factor: 15.609

6.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

7.  Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.

Authors:  Fumiko Taguchi; Benjamin Solomon; Vanesa Gregorc; Heinrich Roder; Robert Gray; Kazuo Kasahara; Makoto Nishio; Julie Brahmer; Anna Spreafico; Vienna Ludovini; Pierre P Massion; Rafal Dziadziuszko; Joan Schiller; Julia Grigorieva; Maxim Tsypin; Stephen W Hunsucker; Richard Caprioli; Mark W Duncan; Fred R Hirsch; Paul A Bunn; David P Carbone
Journal:  J Natl Cancer Inst       Date:  2007-06-06       Impact factor: 13.506

8.  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

Authors:  Edward S Kim; Vera Hirsh; Tony Mok; Mark A Socinski; Radj Gervais; Yi-Long Wu; Long-Yun Li; Claire L Watkins; Mark V Sellers; Elizabeth S Lowe; Yan Sun; Mei-Lin Liao; Kell Osterlind; Martin Reck; Alison A Armour; Frances A Shepherd; Scott M Lippman; Jean-Yves Douillard
Journal:  Lancet       Date:  2008-11-22       Impact factor: 79.321

9.  Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.

Authors:  Vanesa Gregorc; Silvia Novello; Chiara Lazzari; Sandro Barni; Michele Aieta; Manlio Mencoboni; Francesco Grossi; Tommaso De Pas; Filippo de Marinis; Alessandra Bearz; Irene Floriani; Valter Torri; Alessandra Bulotta; Angela Cattaneo; Julia Grigorieva; Maxim Tsypin; Joanna Roder; Claudio Doglioni; Matteo Giaj Levra; Fausto Petrelli; Silvia Foti; Mariagrazia Viganò; Angela Bachi; Heinrich Roder
Journal:  Lancet Oncol       Date:  2014-05-13       Impact factor: 41.316

10.  Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review.

Authors:  Abdul-Rahman Jazieh; Reem Al Sudairy; Nada Abu-Shraie; Wafaa Al Suwairi; Mazen Ferwana; M Hassan Murad
Journal:  Ann Thorac Med       Date:  2013-10       Impact factor: 2.219
View more
  1 in total

1.  Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials.

Authors:  Raymond U Osarogiagbon; Federico Cappuzzo; Tudor Ciuleanu; Larry Leon; Barbara Klughammer
Journal:  Transl Lung Cancer Res       Date:  2015-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.